Shopko launches pharmacy smartphone app
GREEN BAY, Wis. — Mass merchandise chain Shopko has launched a new mobile application for pharmacy customers, the chain said Tuesday.
Fresh off the heals of its merger with Pamida, Shopko announced the launch of an app for Blackberry, Android and iPhone users that will allow customers to refill and manage their pharmacy prescriptions.
Customers using the app can request refills, review active prescription details — including expiration dates, refills remaining and overdue refills — set up dosage reminders and receive email and text notifications when a refill is ready. It also includes a pharmacy locator that allows customers to locate and get driving directions to a pharmacy while checking hours of operation.
"We are always exploring new ways to improve customer service and make our pharmacy services more convenient, and this app makes finding our stores and filling prescriptions on their mobile devices quick and easy for our customers," Shopko president, chairman and CEO Paul Jones said. "This app is in direct response to consumer demand, and we’ve worked hard to develop the features most important to our customers. This will be a convenient and simple new way to access our award-winning pharmacy services."
No comments found
Shire acquires U.S. rights to constipation drug
PHILADELPHIA — Shire has acquired U.S. rights to a drug used to treat chronic constipation in women from Johnson & Johnson, the company said Tuesday.
Shire announced the acquisition of rights to Resolor (prucalopride) from J&J subsidiary Janssen Pharmaceuticals. Financial terms were not disclosed.
Shire acquired European rights to the drug in 2010 when it bought Belgian drug maker Movetis, which itself had acquired rights to the drug from Janssen.
No comments found
Hospira enrolls first patient in biosimilar trial
LAKE FOREST, Ill. — Generic drug maker Hospira has enrolled the first patient in a late-stage clinical trial of a biosimilar drug for treating kidney disease.
The company said the phase-3 trial of biosimilar EPO (erythropoietin) would compare its product with Amgen’s Epogen in patients with kidney dysfunction who have anemia. The trial, which will enroll about 1,000 patients who already have taken Epogen, follows a phase-1 trial that ended last year, and results of the late-stage trial are expected next year.
"Patient enrollment in our phase-3 EPO program is another important step as Hospira prepares to introduce safe, effective and affordable biosimilars in the United States," Hospira chief science officer and SVP research and development and medical and regulatory affairs Sumant Ramachandra said. "We look forward to offering U.S. patients access to these important medications."
Along with Teva Pharmaceutical Industries and Sandoz, Hospira sells biosimilars in Europe, where they already have been legal for a few years. There, it markets a version of EPO called Retacrit, which it launched in 2008, and in 2010, it launched Nivestim (filgrastim), a biosimilar version of Amgen’s Neupogen, used to treat neutropenia, a condition often caused by cancer drugs that causes the body to make too few white blood cells. It also launched Nivestim in Australia last year.
neutroppenia caused by cancer drugs!! This is a case where the operation was a successbut the patient died.My late daughter inlaw (succuimbed to brain cancer) was given the poly cocktail of cancer drugs-and including gamma ray directly to the brain.My dear friend (still surviving)after heavy dosing of anti cancer drugs for breast cancer-now has heart disease,copd,brittle teeth,arthritis--this poly pharmacy of cancer drugs has to be re-examined and more thoroughly evaluated.